|Koji Tamada||Director, Chief Scientific and Medical Officer (CSMO)|
|Hironari Hashioka||Corporate Auditor|
Hidenobu Ishizaki, M.D., Ph.D. Founder and President
Dr. Hidenobu Ishizaki is one of our co-founder and has served as our Chief Executive Officer. In 1996, Dr. Ishizaki received a M.D. from University of Miyazaki. He completed his internship and residency in surgery at Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, and his fellowship at Showa University Northern Yokohama Hospital. In 2007, he received Ph.D. from Graduate School of Medicine, The University of Tokyo. He developed antiangiogenic cancer vaccine targeting tumor endothelial cells, and it was conducted in multi-institutional clinical trials in Japan. After receiving license of Ph.D., Dr, Ishizaki was a postdoctoral research fellow at the Division of Translational Vaccine research and Department of General and Oncologic Surgery, City of Hope National Medical Center until 2010. He has over 7 years’ experience in vaccine development against cancer. After leaving City of Hope, he returned to University of Miyazaki Hospital as a colorectal surgeon. In 2015, Dr. Ishizaki founded Noile-Immune Biotech Inc. with his partners and collaborators to pursue novel cancer immunotherapy development.
Koji Tamada, M.D., Ph.D. Founder
Professor, Department of Immunology, Yamaguchi University Graduate School of Medicine
Professor, Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo
After graduating from Kyushu University School of Medicine, Dr. Tamada acquired a Ph. D. in cancer immunology research. He then traveled to the United States and has engaged in R&D (research and development) for state-of-the-art cancer immunotherapy for the next 13 years. After devoting himself to study at Dr. Lieping Chen's research laboratory at Mayo Clinic's department of immunology, he gained independence at Johns Hopkins University as an assistant professor. He later became the leader of the basic research department for the cancer immunotherapy program at Maryland State University's Cancer Center. He has performed cloning and functionality analysis of PD-L1 (B7-H1) with Dr. Lieping Chen, and contributed to the application of cancer immunotherapy with immune checkpoint inhibition. He is currently actively advancing the development of functional control technology of immune-related molecules and the development of new cancer immunotherapy using genetically modified technology.
Satoshi Wada, M.D., Ph.D. Founder
Vice director, Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute
After graduating from Gunma University School of Medicine, Dr. Wada entered the Surgery I program (currently the Department of General Surgical Science) of the same school and studied digestive organ, liver, gallbladder and pancreatic surgery. After entering the graduate school of the same school through a related hospital, he gained his Ph. D. researching cancer immunotherapy at The Institute of Medical Science, The University of Tokyo. He then conducted researches as a postdoctoral fellow under Dr. Drew Pardoll and Dr. Charles Drake at John Hopkins University and worked as an assistant professor at Gunma University after returning to Japan until his current job. He has been involved in the development of new cancer vaccine therapy targeting new blood vessels and composite immunotherapy based on GM-CSF-producing cancer vaccines. He has further worked on the development of combination antibody therapy using anti-CTLA-4 and LAG-3 antibodies, combination therapy with cancer immunotherapy and radiotherapy, cancer stem cell target immunotherapy, and the identification of new cancer antigens in patient cancer tissue using immunodeficient mouse (NOG mice).
Yukimi Sakoda, M.D., Ph.D.
Associate Professor, Department of Immunology, Yamaguchi University Graduate School of Medicine
Richard D. Schulick, M.D., M.B.A, FACS.
Professor & Chair of Surgery, University of Colorado School of Medicine